首页> 外文期刊>Chemotherapy: International Journal of Experimental and Clinical Chemotherapy >In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
【24h】

In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.

机译:莫西沙星(BAY 12-8039)对来自六个拉丁美洲国家的呼吸道病原体的体外活性。

获取原文
获取原文并翻译 | 示例
           

摘要

The in vitro antibacterial activity of moxifloxacin (BAY 12-8039) was evaluated against 636 isolates of respiratory tract pathogens. The isolates were collected from July 1997 to August 1998 in the frame of a multinational Latin American study. E-test strips calibrated to read moxifloxacin MIC ranges from 0.002 to 32 &mgr;g/ml were used in susceptibility testing. Weekly quality control tests in each laboratory ensured reproducibility. Laboratories from Argentina, Brazil, Chile, Colombia, Mexico and Uruguay participated. MIC(90) for moxifloxacin were as follows: Streptococcus pneumoniae (304 isolates) 0.25 microg/ml, Haemophilus influenzae (135 isolates) 0.125 microg/ ml, Streptococcus pyogenes (66 isolates) 0.25 microg/ml, Moraxella catarrhalis (62 isolates) 0. 25 microg/ml and methicillin-sensitive Staphylococcus aureus (69 isolates) 0.25 microg/ml. These results agreed with reports from other areas. Moxifloxacin showed excellent activity against respiratory pathogens from participant countries. Copyright 2000 S. Karger AG, Basel
机译:对莫西沙星(BAY 12-8039)的体外抗菌活性针对636株呼吸道病原体进行了评估。在1997年7月至1998年8月间,在一项多国拉丁美洲研究的框架内收集了这些分离株。经校准可读取莫西沙星MIC范围为0.002至32μg/ ml的E-test条用于药敏试验。每个实验室每周进行质量控制测试,以确保可重复性。来自阿根廷,巴西,智利,哥伦比亚,墨西哥和乌拉圭的实验室参加了会议。莫西沙星的MIC(90)如下:肺炎链球菌(304株)0.25微克/毫升,流感嗜血杆菌(135株)0.125微克/毫升,化脓性链球菌(66株)0.25微克/毫升,卡他莫拉菌(62株)0 25微克/毫升和对甲氧西林敏感的金黄色葡萄球菌(69个分离株)0.25微克/毫升。这些结果与其他领域的报告一致。莫西沙星对参与国的呼吸道病原体表现出优异的活性。版权所有2000 S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号